Friday, September 19, 2014 Last update: 8:33 AM
FreshNews.com - All Company Technology News Since 1996

Biotech Industry Applauds Introduction of the High Technology Small Business Research Incentives Act

Companies mentioned in this article: Five Star Equities

NEW YORK, NY -- (Marketwire) -- 09/28/12 -- The Biotechnology Industry has seen increased investor interest in 2012 as it continues to impress with strong gains. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 35 percent this year, more than double the S&P 500 Index's gain of 15 percent. New legislation, increased mergers & acquisition activity as a result of major patent expirations have all been contributing factors to the industry's rapid rise in 2012. Five Star Equities examines the outlook for companies in the Biotech Industry and provides equity research on Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and Dendreon Corporation (NASDAQ: DNDN).

Access to the full company reports can be found at:

www.FiveStarEquities.com/SVNT

www.FiveStarEquities.com/DNDN

The Biotechnology Industry Organization (BIO) has recently praised the introduction of the High Technology Small Business Research Incentives Act. The new legislation would allow investors of joint venture R&D projects to utilize the losses and tax credits.

"Through the tax code, Congress historically has provided opportunities that encourage private investment in pre-revenue, R&D-intensive companies. The early growth of the biotech industry in the 1980s was due in part to the ability of investors to support projects aimed at finding new cures and treatments through similar joint ventures. This legislation will help spur greater private investment in biotech and other R&D intensive industries," BIO's President and CEO Jim Greenwood said in a statement.

Five Star Equities releases regular market updates on the Biotech Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports and industry newsletters.

Savient Pharmaceuticals is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. John P. Hamill was recently named Senior Vice President & Chief Financial Officer of Savient Pharmaceuticals. Shares of the company have nearly doubled in the last month.

Dendreon is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. Dendreon's first product, PROVENGE, was approved by the U.S. Food and Drug Administration (FDA) in April 2010.

Five Star Equities provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. Five Star Equities has not been compensated by any of the above-mentioned companies. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:

www.FiveStarEquities.com/disclaimer

Add to Digg Bookmark with del.icio.us Add to Newsvine


Contact:

Contact:
Five Star Equities
Email Contact